NASDAQ:MESO
Mesoblast Ltd Stock News
$8.52
+0.350 (+4.28%)
At Close: May 28, 2024
Pluristem Therapeutics Shares Jump on Covid-19 Study Results
03:38pm, Friday, 10'th Apr 2020
The Israeli company reported its placenta-based treatment seemed to reduce complications in a small study Continue reading...
NRZ, RIG among premarket gainers
01:17pm, Thursday, 09'th Apr 2020
Tiziana Life Sciences PLC (NASDAQ:TLSA) +68% on inhalable treatment for COVID-19.Nautilus (NYSE:NLS) +43% after stay-at-home effect on sales.Exantas Capital (NYSE:XAN) +37%.Transocean (NYSE:RIG) +30
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 8) * Keros Therapeutics Inc (NASDAQ: KROS) (went public
MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTH’S NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO CONDUCT RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L FOR PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19
11:15pm, Wednesday, 08'th Apr 2020
Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L will be formally evaluated in a randomized, placebo-controlled
Mesoblast's COVID-19 Foray, And Other News: The Good, Bad And Ugly Of Biopharma
09:16pm, Wednesday, 08'th Apr 2020
Mesoblast was up on an IND approval targeting COVID-19. Crinetics announced positive trial data. Bellerophon announced earnings and program updates.
84 Biggest Movers From Yesterday
09:47am, Tuesday, 07'th Apr 2020
Gainers
Immunomedics, Inc. (NASDAQ: IMMU) shares jumped 99.8% to close at $18.78 on Monday after the company said it would stop its Ascent Study due to compelling evidence of...
Afternoon Market Stats in 5 Minutes
04:28pm, Monday, 06'th Apr 2020
Movers Indices • S&P 500 ETF (NYSE:SPY) rose 4.98% to $260.29.• Nasdaq ETF (NASDAQ:QQQ) rose 4.92% to $192.38.• Dow Jones Industrial Average ETF (NYSE:DIA) increased 4.94% to $221.07.• FTSE/Xi
TWO and LADR among premarket gainers
01:16pm, Monday, 06'th Apr 2020
Immunomedics (NASDAQ:IMMU) +111% on positive ADC data in breast cancer.Two Harbors Investment (NYSE:TWO) +39% on Q1 update.Mesoblast (NASDAQ:MESO) +36% on testing remestemcel-L in COVID-19 patients
26 Stocks Moving in Monday's Pre-Market Session
11:12am, Monday, 06'th Apr 2020
Gainers
Mesoblast Limited (NASDAQ: MESO) shares rose 54.8% to $6.50 in pre-market trading after the company received the FDA approval for an investigational new drug application...
NEW YORK, April 06, 2020 -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that it has received.
Mesoblast's (MESO) BLA for Ryoncil Gets FDA Priority Review
06:42am, Friday, 03'rd Apr 2020
The FDA accepts Mesoblast's (MESO) BLA for Ryoncil (remestemcel-L) under a priority review to treat children with steroid-refractory acute graft versus host disease. A decision is pending on Sep 30.
Mesoblast's (MESO) BLA for Ryoncil Gets FDA Priority Review
06:42am, Friday, 03'rd Apr 2020
The FDA accepts Mesoblast's (MESO) BLA for Ryoncil (remestemcel-L) under a priority review to treat children with steroid-refractory acute graft versus host disease. A decision is pending on Sep 30.
The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests
11:38am, Wednesday, 01'st Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 31) * Athersys Inc (NASDAQ: ATHX) * Forty Seven Inc (NA
FDA ACCEPTS MESOBLAST’S BIOLOGICS LICENCE APPLICATION FOR RYONCIL™ AND AGREES TO PRIORITY REVIEW
10:00am, Wednesday, 01'st Apr 2020
NEW YORK, April 01, 2020 -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the United States.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Be
